Overview
Portfolio
More
Asabys Partners
Barcelona, Spain
Asabys Partners is a Barcelona‑based venture capital firm investing across the healthcare and life‑science sectors. It focuses on early‑stage biotech, medtech and digital health companies that develop breakthrough therap...
Portfolio
27+
Employees
20+
Founded
2018
AUM
≈ $387.0M
Investment focus
Stages
Pre-Seed → Series A
Industries
BiotechnologyDigital Health
Geographic scope
EuropeNorth America
Fund details
Funds
Sabadell Asabys Health Innovation Investments II (SAHII II)
Vintage 2024 • $198.0M
Agomab Series D
Vintage 2024 • $89.0M
Agomab Series C
Vintage 2023 • $100.0M
Sources
Asabys Partners
Asabys Partners is a Barcelona‑based venture capital firm investing across the healthcare and life‑science sectors. It focuses on early‑stage biotech, medtech and digital health companies that develop breakthrough therapies and technologies addressing unmet medical needs. The firm leverages its strong network in Spain and the EU, while also supporting selective opportunities in North America and other regions.
Portfolio
27+
Employees
20+
Founded
2018
AUM
≈ $387.0M
Funds
Sabadell Asabys Health Innovation Investments II (SAHII II) · Vintage 2024 • $198.0M
Agomab Series D · Vintage 2024 • $89.0M
Agomab Series C · Vintage 2023 • $100.0M
Stages
Pre-Seed → Series A
Industries
BiotechnologyDigital Health
Geographic scope
EuropeNorth America
Sources
Showing 24 of 26 matched portfolio companies
Accure Therapeutics is a pharmaceutical R&D company focused on developing treatments for central nervous system (CNS) disorders, utilizing a distinct approach to drug development that includes the gelatinase inhibitor ACT-03. The company addresses the significant medical challenge posed by CNS diseases, which affect 14% of the global population and incur annual costs of $1.5 trillion.
Provides a community-driven platform for discovering emerging artists, creatives, and brands across industries like music, fashion, and art. It addresses the challenge of visibility for underrepresented talent by connecting them with a global audience through curated exploration tools.
ALLOX utilizes systematic mutagenesis, high-throughput phenotyping, and biophysical modeling to identify allosteric switches in proteins, enabling the rapid development of novel therapeutics for human diseases. By harnessing genetics and AI, the company addresses the challenge of predicting and engineering protein functions, aiming to transform drug discovery and biotechnology.
Amelia is a platform designed to connect ambitious, career-driven women through in-person networking events and mentorship opportunities. By fostering face-to-face interactions, Amelia aims to accelerate women's career advancement and provide access to valuable professional connections.
Anaconda Biomed develops a catheter system designed for mechanical thrombectomies, utilizing a nitinol braided funnel to enhance clot retention and minimize fragmentation during retrieval. This technology addresses the critical need for effective stroke intervention by improving the efficiency and safety of clot removal in patients with acute ischemic stroke.
Funding: $49.6M
Rough estimate of the amount of funding raised
Funding: $49.6M
Rough estimate of the amount of funding raised
Augustine Therapeutics develops a novel class of non‑hydroxamate, non‑hydrazide small‑molecule HDAC6 inhibitors that deliver high selectivity and favorable drug‑like properties, avoiding the off‑target toxicities of earlier chemotypes. Their platform supports both peripherally restricted and brain‑penetrant candidates, enabling therapeutic exploration across neuromuscular, neurodegenerative, cardiometabolic, inflammatory, and autoimmune diseases, with lead programs currently in IND‑enabling or lead‑optimization stages.
Funding: $84.1M
Rough estimate of the amount of funding raised
Funding: $84.1M
Rough estimate of the amount of funding raised
AI-driven platform that optimizes organ donation processes by analyzing donor data and matching it with recipient profiles to improve transplant success rates. It addresses the critical shortage of viable organs by streamlining donor-recipient matching and reducing waitlist times.
Founded 2023
Deep offers a suite of validated sleep solutions, including at-home diagnostics, cognitive therapy, and telemedicine consultations with licensed specialists, all accessible through a mobile app. The platform addresses the widespread issue of poor sleep quality by providing personalized coaching and tailored treatment plans to improve sleep health and overall well-being.
Gradient Denervation Technologies is developing a minimally invasive ultrasound-based catheter system for the transvascular treatment of pulmonary hypertension in heart failure patients. This technology targets elevated pulmonary vascular resistance, aiming to improve cardiovascular health and patient outcomes.
15+
1K+Approximate amount of employees
Funding: $15.0M
Rough estimate of the amount of funding raised
Funding: $15.0M
Rough estimate of the amount of funding raised
IB is an insurance management app that digitizes and consolidates users' insurance policies, allowing for easy access and sharing among family members. The platform identifies potential claims based on user-reported incidents, helping to prevent missed opportunities for insurance payouts.
Funding: $2.8M
Rough estimate of the amount of funding raised
Funding: $2.8M
Rough estimate of the amount of funding raised
This company develops an end-to-end neural platform combining hardware and data analytics to decode and modulate neural networks for treating neurological disorders. Their technology utilizes high-resolution, flexible graphene-based brain-computer interfaces for closed-loop neural decoding and modulation. The platform aims to restore function or mobility for patients through personalized, AI-powered therapy management.
Funding: $73.3M
Rough estimate of the amount of funding raised
Funding: $73.3M
Rough estimate of the amount of funding raised
Koa Health provides a unified digital platform that delivers evidence-based mental health care through clinician-designed care mapping, addressing the need for accessible mental health solutions in organizations. By offering population-level insights and clinical coverage across the mental health continuum, Koa Health enhances employee wellbeing and reduces associated risks and costs.
75+
10K+Approximate amount of employees
Funding: $68.3M
Rough estimate of the amount of funding raised
Funding: $68.3M
Rough estimate of the amount of funding raised
The startup develops bioidentical therapeutics aimed at reeducating dysregulated immune systems to facilitate functional tissue recovery. Their expertise spans therapeutic areas including infectious diseases and metabolic disorders, enabling clients to effectively manage inflammatory diseases and syndromes.
Founded 2017
1000+
Approximate amount of employees
Funding: $750.0K
Rough estimate of the amount of funding raised
Funding: $750.0K
Rough estimate of the amount of funding raised
Nuage Therapeutics develops selective small molecule modulators targeting intrinsically disordered proteins using proprietary assays and chemical biology techniques. The company focuses on treating castration-resistant prostate cancer and other diseases associated with undruggable proteins, addressing significant unmet medical needs in the pharmaceutical landscape.
Funding: $18.4M
Rough estimate of the amount of funding raised
Funding: $18.4M
Rough estimate of the amount of funding raised
Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.
Funding: $250.0K
Rough estimate of the amount of funding raised
Funding: $250.0K
Rough estimate of the amount of funding raised
Omo provides a user interface for stablecoin payments across various blockchain networks and wallets, facilitating seamless transactions while maintaining self-custody. The platform addresses the complexity of crypto payments by simplifying the user experience, although it is currently in early access and not generally available.
ON is an AI chat platform designed for enterprise use, integrating with e-commerce systems like Shopify to enhance customer interactions by providing real-time access to product and order information. This technology addresses the high volume of customer service inquiries, improving site conversions and customer satisfaction while reducing the workload for support agents.
Funding: $25.0M
Rough estimate of the amount of funding raised
Funding: $25.0M
Rough estimate of the amount of funding raised
Ona Therapeutics develops first‑in‑class antibody‑drug conjugates (ADCs) that target novel antigens discovered from the biology of treatment‑refractory advanced cancers. By partnering with academic and clinical researchers, they identify molecular changes in resistant tumors and engineer precision ADCs with optimized pharmacokinetics and payload delivery, advancing only candidates with strong preclinical efficacy and safety.
Funding: $11.6M
Rough estimate of the amount of funding raised
Funding: $11.6M
Rough estimate of the amount of funding raised
Orikine develops precision-engineered, bi-specific cytokines using a versatile protein-design platform to treat autoimmune and inflammatory diseases. Their Foldikine™ technology reprograms immune signaling by creating optimized cytokine therapeutics for targeted efficacy and safety. This approach aims to deliver precise immune modulation with enhanced durability and a higher therapeutic index.
Funding: $6.8M
Rough estimate of the amount of funding raised
Funding: $6.8M
Rough estimate of the amount of funding raised
Peptomyc develops cell-penetrating mini-proteins that directly inhibit MYC, a critical transcription factor involved in cancer proliferation and resistance. By targeting MYC dysregulation, which occurs in approximately 70% of cancers, Peptomyc aims to improve treatment efficacy and patient outcomes across various cancer types.
Funding: $3.3M
Rough estimate of the amount of funding raised
Funding: $3.3M
Rough estimate of the amount of funding raised
Qi is a UK-based FinTech provider specializing in blockchain payment processing, offering seamless crypto transactions and blockchain infrastructure to businesses. Their solutions enhance financial inclusion by bridging traditional payment systems with digital asset capabilities, enabling companies to expand their customer base in the evolving web3-commerce landscape.
Funding: $230.0K
Rough estimate of the amount of funding raised
Funding: $230.0K
Rough estimate of the amount of funding raised
SafeHeal has developed Colovac, a colorectal anastomosis protection device that minimizes fecal contact at the anastomotic site after surgery. This technology aims to reduce the risk of anastomotic leaks, potentially eliminating the need for diverting ostomies in patients undergoing colectomy.
Funding: $52.7M
Rough estimate of the amount of funding raised
Funding: $52.7M
Rough estimate of the amount of funding raised
Sense is a digital platform that allows users to aggregate and manage product preferences from any physical or online store in one centralized location. By enabling easy saving and sharing of products, Sense addresses the challenge of fragmented shopping experiences, facilitating informed purchasing decisions and supporting local businesses.
Funding: $320.0K
Rough estimate of the amount of funding raised
Funding: $320.0K
Rough estimate of the amount of funding raised
Provides a dedicated video conferencing device designed for remote teams to conduct scheduled coworking sessions, fostering casual collaboration and spontaneous conversations. By replacing traditional tools like Zoom, it eliminates the need for constant event planning and enables seamless 1:1 chats, improving team culture and productivity.
Funding: $150.0K
Rough estimate of the amount of funding raised
Funding: $150.0K
Rough estimate of the amount of funding raised
Showing 1 of 1 unmatched portfolio company